Genesis Laboratory Management, LLC

Genesis Laboratory Management, LLC was paid $21.75M by Medicaid between Jan 2018 and Dec 2024, across 64 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 64% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in New Jersey

Rank by total paid#18 of 122

Median peer was paid$1.29M

This provider vs. median17×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	7,001	$723K
2019	14,394	$1.10M
2020	62,437	$4.27M
2021	203,259	$8.41M
2022	181,063	$5.28M
2023	75,046	$1.35M
2024incomplete	27,721	$612K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	64%	225,105	176,029	$13.85M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	13%	159,094	121,772	$2.93M
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	4.4%	2,963	2,761	$959K
0241U	Neonatal screening for hereditary disorders, genomic sequence analysis panel	3.0%	7,164	5,435	$657K
88364		2.7%	3,265	3,237	$595K
87507		1.9%	1,467	1,449	$423K
87150		1.6%	8,492	6,445	$357K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	1.4%	7,217	5,393	$294K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	1.2%	8,526	6,973	$259K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	6,759	5,720	$204K
88365		<1%	3,274	3,248	$200K
87581		<1%	8,031	6,300	$123K

52 more codes

87506		<1%	2,671	$95K
0202U	Oncology (prostate), multianalyte, gene expression profiling	<1%	173	$65K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	4,361	$63K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	3,008	$61K
88342		<1%	2,385	$54K
87486		<1%	8,166	$54K
88313		<1%	3,574	$54K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	6,923	$54K
83520		<1%	6,914	$46K
87634		<1%	4,212	$44K
87631		<1%	1,450	$35K
87541		<1%	5,074	$31K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	9,754	$27K
87496		<1%	3,955	$24K
87532		<1%	3,889	$19K
87503		<1%	4,282	$19K
87498		<1%	3,891	$17K
83631		<1%	6,018	$15K
88312		<1%	1,582	$14K
83993		<1%	5,491	$12K
86769		<1%	491	$12K
87209		<1%	5,168	$11K
82656		<1%	6,222	$9K
87338		<1%	5,382	$9K
82657		<1%	1,741	$9K
82274		<1%	5,851	$7K
87177		<1%	5,219	$6K
87500		<1%	1,206	$5K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	146	$4K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	74	$3K
87324		<1%	552	$2K
82705		<1%	4,785	$2K
89055		<1%	2,987	$2K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	<1%	25	$2K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	721	$1K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	74	$1K
87481		<1%	56	$1K
87640		<1%	248	$1K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	55	$808.73
87529		<1%	16	$608.00
88142		<1%	27	$604.04
87641		<1%	399	$603.74
0097U		<1%	48	$304.96
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	28	$263.09
87511		<1%	14	$190.00
87653		<1%	33	$173.30
87505		<1%	18	$83.80
80053	Comprehensive metabolic panel	0%	58	$0.00
85025	Blood count; complete (CBC), automated, and automated differential WBC count	0%	107	$0.00
84443	Thyroid stimulating hormone (TSH)	0%	13	$0.00
86140		0%	12	$0.00
80061	Lipid panel	0%	15	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialFLETCHER, SHARRON (CFO)